Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease
Open Access
- 12 June 2021
- journal article
- research article
- Published by Elsevier BV in European Urology Open Science
- Vol. 29, 93-101
- https://doi.org/10.1016/j.euros.2021.05.004
Abstract
No abstract availableFunding Information
- Prostate Cancer Canada
- Prostate Cancer Foundation
This publication has 22 references indexed in Scilit:
- Molecular Subtypes of Prostate CancerCurrent Oncology Reports, 2018
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate CancerThe New England Journal of Medicine, 2016
- ATM protein is deficient in over 40% of lung adenocarcinomasOncotarget, 2016
- Molecular subtyping of prostate cancerCurrent Opinion in Urology, 2016
- SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker developmentUrologic Oncology, 2015
- Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosisJournal of Hematology & Oncology, 2014
- Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration‐resistant prostate cancerHistopathology, 2012
- Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerBritish Journal of Cancer, 2010
- Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of DiagnosisJNCI Journal of the National Cancer Institute, 2009
- Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell lineOncogene, 2002